Human hepatocellular carcinoma-infiltrating CD4 + CD69 + Foxp3 − regulatory T cell suppresses T cell response via membrane-bound TGF-β1
Yanmei Han,Yuan Yang,Zhubo Chen,Zhengping Jiang,Yan Gu,Yanfang Liu,Sheng Xu,Chuan Lin,Zeya Pan,Weiping Zhou,Xuetao Cao
DOI: https://doi.org/10.1007/s00109-014-1143-4
2014-01-01
Abstract:Tumors can recruit, induce, and expand regulatory T cells (Tregs) to suppress antitumor immune responses for survival and progression. The complicated tumor-related Treg subsets and their functional mechanisms are not fully addressed yet. We have previously identified a novel CD4 + CD69 + CD25 − Foxp3 − Treg subset in tumor-bearing mice, which suppresses CD4 T cell response via membrane-bound transforming growth factor beta 1 (mTGF-β1) and then promotes tumor progression. In hepatocellular carcinoma patients, here, we identified tumor-infiltrating human CD4 + CD69 + Tregs which represent ~67.2 % of tumor-infiltrating CD4 T cells that is significantly higher than conventional CD4 + CD25 + Foxp3 + Tregs. They expressed mTGF-β1, PD-1, and CTLA-4, but not CD25 or Foxp3, and only produced a little interleukin (IL)-10 and TGF-β1. More importantly, they significantly suppressed CD4 T cell response via mTGF-β1 in vitro. Furthermore, the percentage of these CD4 + CD69 + Tregs in tumor tissue was significantly correlated with tumor progression, which is more pronounced at the late stage of cancer patients. Thus, we have identified a tumor-induced new population of human CD4 + CD69 + Tregs in cancer patients with phenotype of CD25 − Foxp3 − mTGF-β1 + CTLA-4 + PD-1 + , and these Tregs can suppress antitumor immune response via mTGF-β1. Our results not only enrich the family of Treg subsets, providing new mechanistic insight to tumor-induced immune suppression in human, but also suggest a potential target for cancer immunotherapy. Key message CD4 + CD69 + Foxp3 − regulatory T cells were identified in hepatocellular carcinoma patients. These Treg cells inhibit T cell response via membrane-bound TGF-β. The percentage of these cells was significantly correlated with tumor progression. The percentage of these cells was higher than conventional CD4 + CD25 + Foxp3 + Tregs. These Treg cells not only exist in tumor-bearing mice, but also in cancer patients.